- Drugs
- Monday, 27 Apr 2020
Alligator Bioscience Presents Promising Interim Phase I Data for its Bispecific Drug Candidate ATOR-1015 at AACR
Alligator Bioscience, announces that the company today presents the status of the ongoing Phase I clinical trial with the bispecific drug candidate ATOR-1015 developed as tumor-directed therapy for metastatic cancer. The presentation will take place at the AACR (American Association for Cancer Research) Annual Meeting, which this year is being held digital for the first time.
This far, doses of 400 mg (about 6 mg/kg) have been evaluated in the ongoing study and the current dosing is 600 mg (about 10 mg/kg). 18 patients with varying cancer forms (colon cancer, eye melanoma, pancreatic cancer, ovarian cancer, gallbladder cancer, gastric cancer and skin cancer) have been treated and evaluated in terms of safety. ATOR-1015 has so far been well tolerated.
"We are very proud and happy that our study has been selected for presentation. The promising results so far demonstrate that ATOR-1015 can be administered safely. ATOR-1015 has the potential to be at least as effective as today's available treatment for these patients, but with significantly fewer side effects," said Per Norlén, CEO of Alligator Bioscience.
The adverse events in the study were generally mild and transient, all of grade 1 or 2 (on a scale of 1-5). The most common adverse events were infusion-related reactions (five patients). No serious immune-related or dose-limiting adverse events have been reported.
The presentation with the title "A first-in-human phase 1 study in patients with advanced and/or refractory solid malignancies to evaluate the safety of ATOR-1015, a CTLA-4 x OX40 bispecific antibody" will be held by Charlotte Russell, Chief Medical Officer at Alligator Bioscience. The presentation is available through the link below between 9:00 a.m. - 6:00 p.m. EDT (3 p.m.-12 a.m. CEST) today and will also be available on the company website www.alligatorbioscience.com. https://www.abstractsonline.com/pp8/#!/9045/presentation/10644
Related Industry Updates
Australia & South Korea Diabetic Foot Ulcer Market is expected to reach US$ 313.53 billion by 2030
Sep 20, 2023
North America Vaccines Market is Estimated to Grow with a CAGR of 6.0% from 2019-2027
Sep 25, 2020
US Intravenous Immunoglobulin Market is expected to reach US$ 7,105.63 million by 2028
Apr 19, 2023
China Transmucosal Drug Delivery Systems Market Research With Size, Growth, Manufacturers, Segments And 2027 | 3M, Acrux, GW Pharmaceuticals
Feb 05, 2021
Global Recall of the Common Heartburning Drugs Over the Risk of Cancer
Jan 21, 2020
Non-Gelatin Empty Capsules Market is expected to reach US$ 4.64 billion by 2030
Feb 14, 2024
Augmenting Cases of Chronic Diseases has increased the usage of Radiopharmaceutical
Sep 06, 2019